Concentric Tumor Shrinkage by Chemotherapy is a Good Prognostic Factor in Neoadjuvant Chemotherapy for Luminal Breast Cancer
| Autor: | C. Tsutsumi, Takayuki Kobayashi, Kiyohiko Hatake, Yoshie Nakayama, Yoshinori Ito, Y. Kawai, Ippei Fukada, Kokoro Kobayashi, S. Takahashi |
|---|---|
| Rok vydání: | 2012 |
| Předmět: |
Oncology
Chemotherapy Prognostic factor medicine.medical_specialty business.industry medicine.medical_treatment Residual cancer Tumor shrinkage Hematology Favorable prognosis medicine.disease Breast cancer Internal medicine Cancer cell Medicine Immunohistochemistry skin and connective tissue diseases business |
| Zdroj: | Annals of Oncology. 23:xi126-xi127 |
| ISSN: | 0923-7534 |
| Popis: | Background and objective The important characteristics of breast cancer is its heterogeneity and attitude of response to neoadjuvant chemotherapy (NAC). We analyzed the patterns of tumor shrinkage as a prognostic indicator after NAC for luminal breast cancer. Methods and results Of the 503 patients who had received NAC in our hospital between January 2000 and December 2007, 142 luminal breast cancer were included in this study. Luminal breast cancer was defined as ER and/or PgR-positive in more than 10% of cancer cells and HER2 negative (IHC 0, 1+ or FISH Discussion The results suggest that concentric tumor shrinkage tends to be associated with a favorable prognosis, whereas scattered residual cancer cells are resistant to chemotherapy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|